97-23729. Advisory Committee; Notice of Meeting  

  • [Federal Register Volume 62, Number 173 (Monday, September 8, 1997)]
    [Notices]
    [Pages 47211-47212]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 97-23729]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    
    Advisory Committee; Notice of Meeting
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
        This notice announces a forthcoming meeting of a public advisory 
    committee of the Food and Drug Administration (FDA). At least one 
    portion of the meeting will be closed to the public.
        Name of Committee: Clinical Chemistry and Clinical Toxicology 
    Devices Panel of the Medical Devices Advisory Committee.
    
    [[Page 47212]]
    
        General Function of the Committee: To provide advice and 
    recommendations to the agency on FDA regulatory issues.
        Date and Time: The meeting will be held on September 25, 1997, 8 
    a.m. to 4 p.m.
        Location: Holiday Inn, Versailles Ballrooms III and IV, 8120 
    Wisconsin Ave., Bethesda, MD.
        Contact Person: Sharon K. Lappalainen, Center for Devices and 
    Radiological Health (HFZ-440), Food and Drug Administration, 2098 
    Gaither Rd., Rockville, MD 20850, 301-594-1243, or FDA Advisory 
    Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
    Washington, DC area), code 12514. Please call the Information Line for 
    up-to-date information on this meeting.
        Agenda: The committee will provide advice and recommendations to 
    the agency regarding over-the-counter drugs of abuse testing systems 
    and comment on a draft points-to-consider document for these products. 
    Single copies of the draft points-to-consider document entitled 
    ``Points to Consider for Approval of Home Drugs of Abuse Test Kits'' 
    are available to the public by contacting the Division of Small 
    Manufacturers Assistance, 1350 Piccard Dr., Rockville, MD 20851, 1-800-
    638-2041, or on the Internet using the World Wide Web (WWW) (http://
    www.fda.gov/cdrh/draftgui.html).
        Procedure: On September 25, 1997, from 9 a.m. to 4 p.m., the 
    meeting is open to the public. Interested persons may present data, 
    information, or views, orally or in writing, on issues pending before 
    the committee. Written submissions may be made to the contact person by 
    September 18, 1997. Oral presentations from the public will be 
    scheduled between approximately 9 a.m. and 10 a.m. Time allotted for 
    each presentation may be limited. Those desiring to make formal oral 
    presentations should notify the contact person before September 18, 
    1997, and submit a brief statement of the general nature of the 
    evidence or arguments they wish to present, the names and addresses of 
    proposed participants, and an indication of the approximate time 
    requested to make their presentation.
        Closed committee deliberations: On September 25, 1997, from 8 a.m. 
    to 9 a.m., the meeting will be closed to permit discussion and review 
    of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)) 
    relating to present and future agency issues.
        Notice of this meeting is given under the Federal Advisory 
    Committee Act (5 U.S.C. app. 2).
    
        Dated: August 28, 1997.
    Michael A. Friedman,
    Deputy Commissioner for Operations.
    [FR Doc. 97-23729 Filed 9-5-97; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
09/08/1997
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
97-23729
Pages:
47211-47212 (2 pages)
PDF File:
97-23729.pdf